125 related articles for article (PubMed ID: 9052473)
1. The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1997 Feb; 79(2):217-20. PubMed ID: 9052473
[TBL] [Abstract][Full Text] [Related]
2. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
[TBL] [Abstract][Full Text] [Related]
4. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
5. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
6. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
8. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
[TBL] [Abstract][Full Text] [Related]
9. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
11. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
[TBL] [Abstract][Full Text] [Related]
13. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
15. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
17. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer.
Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E
Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666
[TBL] [Abstract][Full Text] [Related]
20. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
